SCHEMBL6956005

SCHEMBL6956005

CCC[C@H](C(N)=O)[C@@H](CC(C)C)C(=O)N1CCC(C(N)=O)CC1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CHRM1 P11229 1/20 0.39
CHEK1 O14757 2/20 0.39
POLB P06746 1/20 0.38
MMP1 P03956 1/20 0.37
MMP2 P08253 1/20 0.37
MMP3 P08254 1/20 0.37
MMP8 P22894 1/20 0.37
PKM P14618 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6956004 1.00 GAA (0.44) GAASMN1; SMN2ALDH1A1MEN1LMNA
SCHEMBL7069426 1.00 GAA (0.44) GAASMN1; SMN2ALDH1A1MEN1LMNA
SCHEMBL7068722 0.88 ALDH1A1 (0.45) GAAALDH1A1MEN1KMT2APOLB
SCHEMBL7065488 0.88 DPP4 (0.44) POLBMMP1MMP2MMP3MMP8
SCHEMBL7068719 0.88 ALDH1A1 (0.45) GAAALDH1A1MEN1KMT2APOLB
SCHEMBL7065490 0.88 DPP4 (0.44) POLBMMP1MMP2MMP3MMP8
SCHEMBL6946641 0.87 MAPT (0.49) GAASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL6946636 0.87 MAPT (0.49) GAASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL7068432 0.87 MAPT (0.49) GAASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL6956635 0.86 LMNA (0.50) ALDH1A1LMNAKMT2AMMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030232985-A1 Succinoylamino heterocycles as inhibitors of a beta protein production THOMPSON LORIN A (US) 2003-12-18 US disclosed
US-20030073701-A1 Succinoylamino heterocycles as inhibitors of a beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-04-17 US disclosed
EP-1268454-A1 SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2003-01-02 EP disclosed
WO-2001074796-A1 SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073701-A1 Succinoylamino heterocycles as inhibitors of a beta protein production APP, BACE1, APH1A GAA 156/4885SMN1; SMN2 157/4885ALDH1A1 3091/4885
US-20030232985-A1 Succinoylamino heterocycles as inhibitors of a beta protein production APP, BACE1, APH1A GAA 156/4885SMN1; SMN2 157/4885ALDH1A1 3091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.